Simplifying Diabetes Management and Expanding Access to Insulin Pump Therapy
Modular Medical, Inc. (Nasdaq: MODD) is a medical device company headquartered in San Diego, California, focused on the design, development, and commercialization of innovative insulin pumps using modernized technology to increase pump adoption in the diabetes marketplace.
LATEST NEWS
Modular Medical Announces Pivot Tubeless Insulin Patch Pump Now Commercially Available in the United States
Identifying The Opportunity
KEY LEVELS
Key Level #1 - $5.43
Key Level #2 - $5.88
Key Level #3 - $6.17
Support: $4.43
Modular Medical, Inc.
Products and Technology
- The MODD1 is a two-part patch pump that received FDA 510(k) clearance in September 2024. It features a three-part system with one reusable component and two disposable components, a one-button interface, smartphone connectivity, and a 90-day reusable controller paired with a 3-day disposable cartridge and set.
- The Pivot is the company's next-generation fully tubeless, removable patch pump. It integrates the set into the device body, eliminating tubing entirely, and features a 3 mL detachable insulin reservoir, no battery recharging requirement, smartphone connectivity for bolus dosing, and one-button bolus capability without a separate controller.
- The Pivot received FDA 510(k) clearance on April 9, 2026 and was announced as commercially available in the United States on June 24, 2026, making it only the second fully electronic, tubeless insulin pump available in the country.
- The company's reusable pump architecture is designed to provide a significant cost advantage over competitive all-disposable patch pumps, with the reusable controller lasting 90 days and disposable components replaced every three days.
- Modular Medical also intends to pursue CE mark clearance for both the MODD1 and Pivot products to access European markets.
Market Strategy and Commercial Rollout
- Modular Medical is targeting the large and underserved population of insulin-dependent adults who have been unable or unwilling to adopt existing pump therapy, a segment the company calls "almost-pumpers," across both Type 1 and Type 2 diabetes markets.
- The Pivot's commercial launch is rolling out in phases, initially targeting select high-volume endocrinology practices with broader expansion across multiple metropolitan markets expected by late 2026.
- The company launched a dedicated patient-facing website, PivotPump.com, in June 2026 to support individuals seeking information about insulin pump therapy.
Positioning for Commercial Growth
- Modular Medical transitioned from a development-stage to a commercial-stage company upon the Pivot's launch in June 2026, with the full commercial expansion targeting select high-volume endocrinology practices and then broadening to metropolitan markets by late 2026.
- Phillips-Medisize, a Molex company, serves as tier-one manufacturing partner, providing injection molding, electronics design and manufacturing, packaging, and assembly capabilities, with initial production capacity supporting approximately 6,000 users.
- The company is pursuing insurance reimbursement pathways to reduce co-payment burdens on patients, which it identifies as a core component of expanding adoption. A payor survey showed willingness to grant preferential coverage for a discount of approximately 20% among payors covering roughly one-third of total U.S. covered lives.
Financials
Key Financial Highlights (Nine Months Ended December 31, 2025 — per 10-Q):
- Total Operating Expenses: $21.9 million (up from $14.1 million in the prior year period)
- Research and Development: $16.1 million (up from $10.8 million in the prior year period)
- Selling, General and Administrative: $5.7 million (up from $3.3 million in the prior year period)
- Net Loss: $21.9 million (vs. $13.9 million in the prior year period)
- Net Loss Per Share: $(0.37) (improved from $(0.39) in the prior year period)
- Weighted Average Shares Outstanding: 58.6 million (up from 35.3 million in the prior year period)
Introducing the Leadership Team of Modular Medical, Inc. (Nasdaq: MODD)
Paul DiPerna
Founder and President
Paul DiPerna possesses more than 30 years of experience in the medical device industry as a technologist, business executive, and serial founder. He previously founded Tandem Diabetes Care (TNDM) in 2005 and invented and designed the t:slim insulin pump, which went public at a $450 million IPO in 2013. DiPerna co-invented the Ivera Medical blood-borne infection control device technology, which was acquired by 3M in 2015. He founded Modular Medical in 2015. He holds a Bachelor of Science in Mechanical Engineering from the University of Massachusetts and a Master's in Engineering Management from Northeastern University, and holds more than 70 patents primarily in blood separation technologies, micro pumping, and diabetes care systems.
James "Jeb" Besser
Chief Executive Officer
Jeb Besser was appointed CEO of Modular Medical on February 23, 2022. He previously served for 23 years as Managing Member of Manchester Management LLC, which is the company's largest outside shareholder and has been a development partner since the company's inception. Besser brings more than 25 years of experience in U.S. public equity and capital markets, with a focus in life sciences and technology. He has provided strategic planning, due diligence, business development, and investor relations guidance to more than 100 public companies and has been actively involved in developing Modular Medical's commercial go-to-market strategy since 2017.
Kevin Schmid
Chief Operating Officer
Kevin Schmid was appointed COO in July 2022. He brings more than 40 years of experience in drug delivery and diabetes management. Schmid previously served as Vice President of Operations and Business Development at Insulet Corporation, where he was instrumental in developing, manufacturing, and commercializing the Omnipod Diabetes Management System. He oversaw multi-million unit global supply chains and high-volume manufacturing operations. Most recently prior to joining Modular Medical, Schmid served as CEO of Common Sensing, a manufacturer of disposable injector pen dose monitoring technology that was acquired by Bigfoot Biomedical in 2021. He holds a Bachelor of Science in Mechanical Engineering from Clarkson University and an MBA from Sacred Heart University.
We get our information from SEC filings and verified public sources.
Stay Ahead. Stay Informed. Stay Profitable.
Subscribe to See What They're Watching
Sources
https://www.modularmedical.com/ https://www.sec.gov/ (MODD SEC Filings) https://www.globenewswire.com/ (Press Releases) https://www.nasdaq.com/ (Financial Data) https://www.tradingview.com/symbols/NASDAQ-MODD/
Disclaimer
Disclaimer
Stock Research Today is a project of Virtus Media Group LLC and intended solely for entertainment and informational purposes. This website / media webpage is owned, operated and edited by Virtus Media LLC. Any wording found on this website / media webpage or disclaimer referencing “I” or “we” or “our” or “Virtus Media” refers to Virtus Media LLC. This website / media webpage is a paid advertisement, not a recommendation nor an offer to buy or sell securities. By reading our website / media webpage you agree to the terms of this disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investment or brokerage advice or anything of an advisory or consultancy nature and therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis for making investment decisions and is for entertainment and educational purposes only. At most, this communication should serve as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. Consult your financial, investment and tax advisors to determine what financial and tax strategies may be right for you. Investor protection and other important information is available at https://www.sec.gov/.
By using our service, you agree not to hold our site, its editors, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within or referred to from our website / media webpage. We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Never invest purely based on our alerts. Gains mentioned in our website / media webpage may be based on end-of-day or intraday data.
This publication and its owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. That information is only valid at the time it is published, and we do not undertake to update it.
Virtus Media’s business model is to receive financial compensation to promote public companies and to conduct investor relations advertising, marketing and publicly disseminate information, not limited to our websites, email, sms, push notifications, influencers, social media postings, ticker tags, press releases, online interviews, podcasts, videos, audio ads, banner ads, native ads, and responsive ads. This compensation is a major conflict of interest in our ability to be unbiased regarding the subject of our reports and communications. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the parties who hired us, or of the profiled companies. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts.
The third parties paying for our services, the profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to impact share prices, possibly significantly. Frequently companies profiled in our alerts experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases.
We do not guarantee the timeliness, accuracy, or completeness of the information on our website / media webpage. The information in our website / media webpage is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, Virtus Media often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors.
Pursuant to an agreement between Modular Medical, Inc. and Virtus Media Group LLC, Virtus Media has been hired to publicly disseminate information about ticker $MODD via digital communications beginning June 30th, 2026 ending June 30th, 2026. Virtus will be paid $15,000 from JRZ Capital.
